Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

Ovarian cancer is the seventh most common gynaecologic malignancy seen in women.
Majority of the patients with ovarian cancer are diagnosed at the advanced stage making …

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers
(HGSCs) survive more than five years after diagnosis, but those who have an exceptionally …

Patients with high-grade serous ovarian cancer (HGSC) have experienced little
improvement in overall survival, and standard treatment has not advanced beyond platinum …

The genomic complexity of profound copy number aberrations has prevented effective
molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy …

Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour
types, particularly in high-grade serous ovarian cancer, uterine tumours and gastro …

The fallopian tube secretory cell is the cell of origin for the majority of ovarian cancers.
Although it remains unclear what triggers neoplastic transformation of these cells, certain …

Summary The Cancer Genome Atlas (TCGA) project has analyzed mRNA expression,
miRNA expression, promoter methylation, and DNA copy number in 489 high-grade serous …

Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian
cancer is unclear; reports vary from 3% to 27%. The impact of germ-line mutation on …

We describe methods with enhanced power and specificity to identify genes targeted by
somatic copy-number alterations (SCNAs) that drive cancer growth. By separating SCNA …